Drug intelligence / Profile preview

netilmicin + piperacillin

Development stage: Unknown
Lead developer: Bayer
Modality: Small Molecules
Administration: Intravenous

Overview

A combination antibiotic regimen consisting of netilmicin (an aminoglycoside) and piperacillin (a broad-spectrum ureidopenicillin). This combination provides synergistic activity against many bacterial pathogens, particularly Gram-negative bacteria including *Pseudomonas aeruginosa*. It is primarily used for empirical treatment of serious bacterial infections, especially in neutropenic patients, and for Gram-negative bacteremia.

Targets

PBP (Penicillin-binding protein family)Bacterial Ribosome

Beyond the preview

Go deeper on netilmicin + piperacillin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on netilmicin + piperacillin.

Explore the full profile